08:00 , Dec 10, 2012 |  BC Week In Review  |  Financial News

Theradiag completes IPO

Theradiag , Marne La Vallee, France   Business: Diagnostic   Date completed: 12/6/12   Type: IPO   Raised: €8.2 million ($10.7 million)   Shares: 1.4 million   Price: €5.80   Shares after offering: 3.8 million...
02:20 , Dec 7, 2012 |  BC Extra  |  Financial News

Theradiag raises EUR 8.2 million in IPO

Diagnostics company Theradiag (Marne La Vallee, France) raised EUR 8.2 million ($10.7 million) through the sale of 1.4 million shares at EUR 5.80 in an IPO underwritten by BIL and Portzamparc. The price values Theradiag...
07:00 , Oct 29, 2012 |  BC Week In Review  |  Financial News

Nanobiotix completes IPO

Nanobiotix S.A. , Paris, France   Business: Drug delivery, Cancer   Date completed: 10/24/12   Type: IPO   Raised: €14.3 million ($18.5 million)   Shares: 2.4 million   Price: €6   Shares after offering: 10.7...
00:29 , Oct 25, 2012 |  BC Extra  |  Financial News

Nanobiotix raises EUR 14.2M in French IPO

Nanobiotix S.A. (Paris, France) raised EUR 14.2 million ($18.5 million) through the sale of 2.4 million shares at EUR 6 in an IPO on NYSE Euronext Paris. The EUR 6 price values the company at...
07:00 , Oct 15, 2012 |  BC Week In Review  |  Financial News

Nanobiotix amends IPO

Nanobiotix S.A. , Paris, France   Business: Drug delivery, Cancer   Date announced: 9/10/12   Type: IPO   To be raised: Up to €12.7 million ($16.4 million)   Shares: 2.1 million   Price: €5.04-€6.16  ...
00:30 , Oct 12, 2012 |  BC Extra  |  Financial News

Nanobiotix sets IPO range

Nanobiotix S.A. (Paris, France) set the proposed price range and number of shares for its IPO on NYSE Euronext Paris at up to 2.1 million shares and EUR 5.04-EUR 6.16. At the EUR 5.60 midpoint,...
08:00 , Mar 10, 2000 |  BC Extra  |  Financial News

Axxima raises DM20 million

Signal transduction company Axxima (Martinsried, Germany) raised DM20 million ($9.8 million) in a venture round. Investors included TVM; International Biotechnology Trust; Alpinvest; Global Life Science Ventures; IKB; tbg; Biotechnology Investments Ltd., which is being transferred...
08:00 , Jan 31, 2000 |  BioCentury  |  Finance

Here comes the paper

The dike has given way, as 13 biotech financings closed last week, raising $652 million. The industry has raised $1.5 billion in the first four weeks of 2000. Although the torrent can't be sustained -...
08:00 , Jan 28, 2000 |  BC Extra  |  Top Story

3i replaces Rothschild at BIL

3i Asset Management will replace Rothschild Asset Management as the manager of assets of Biotechnology Investments Ltd. (LSE:BIYA). The BIYA board is proposing the liquidation of BIYA and the transfer of the assets to a...
07:00 , Oct 18, 1999 |  BioCentury  |  Emerging Company Profile

Eos Biotechnology Inc.

Eos Biotechnology Inc. South San Francisco, Calif. Technology: Genomics technologies integrated with in vitro and in vivo biology Disease focus: Cancer, cardiovascular and autoimmune disorders Clinical status: Preclinical Founded: 1997 by Herb Heinaker, Steve Weiss,...